OFG
NBIX icon

OmniStar Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

OmniStar Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,300
Closed -$286K – 241
2020
Q1 		$286K Buy
3,300
+221
+7% +$21.6K 0.28% 90
2019
Q4 		$331K Buy
3,079
+2
+0.1% +$209 0.28% 93
2019
Q3 		$277K Buy
+3,077
New +$287K 0.24% 92

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OmniStar Financial Group's NBIX Position: Q2 2020 in Review

OmniStar Financial Group sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 3,300 shares — an estimated $286K sold.

OmniStar Financial Group first reported a position in NBIX in Q3 2019 and held it in 3 quarters. The position peaked at $331K in Q4 2019. 418 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • OmniStar Financial Group reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
  • OmniStar Financial Group sold 3,300 Neurocrine Biosciences shares in Q2 2020, an estimated $286K.
  • OmniStar Financial Group first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 3 quarters.
  • OmniStar Financial Group's Neurocrine Biosciences position peaked at $331K in Q4 2019.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on OmniStar Financial Group's 13F filing for Q2 2020, filed 6 Jul 2020.